Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and venereology task forces on quality of life and patient oriented outcomes, melanoma and non‐melanoma skin cancer

Chernyshov, P.V., Lallas, A., Tomas-Aragones, L., Arenbergerova, M., Samimi, M., Manolache, L., Svensson, A., Marron, S.E., Sampogna, F., Spillekom-vanKoulil, S., Bewley, A., Forsea, A.M., Jemec, G.B., Szepietowski, J.C., Augustin, M. and Finlay, A.Y. ORCID: https://orcid.org/0000-0003-2143-1646 2019. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and venereology task forces on quality of life and patient oriented outcomes, melanoma and non‐melanoma skin cancer. Journal of the European Academy of Dermatology and Venereology 33 (5) , pp. 816-827. 10.1111/jdv.15487

Preview

PDF - Accepted Post-Print Version Download (207kB) | Preview

Abstract

The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer (NMSC) present a review of the literature and position statement on health‐related (HR) QoL assessment in skin cancer patients. A literature search was carried out to identify publications since 1980 that included information about the impact of SC on QoL. Generic, dermatology‐specific, cancer‐specific, SC‐specific, facial SC‐specific, NMSC‐specific, basal cell carcinoma‐specific and melanoma‐specific QoL questionnaires have been used to assess HRQoL in SC patients. HRQoL was assessed in the context of creation and validation of the HRQoL instruments, clinical trials, comparison of QoL in SC and other cancers, other diseases or controls, HRQoL assessment after treatment, comorbidities, behaviour modification, predictors of QoL and survival, supportive care needs, coping strategies and fear of cancer recurrence. The most widely used instruments for HRQoL assessment in SC patients are the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ‐C30), the Functional Assessment of Cancer Therapy‐Melanoma (FACT‐M), Skin Cancer Index (SCI), Short Form 36 Item Health Survey (SF‐36) and the Dermatology Life Quality Index (DLQI). The TFs recommend the use of the cancer‐specific EORTC QLQ‐C30, especially in late stages of disease, and the melanoma‐specific FACT‐M and SC‐specific SCI questionnaires. These instruments have been well validated and used in several studies. Other HRQoL instruments, also with good basic validation, are not currently recommended because the experience of their use is too limited. Dermatology‐specific HRQoL instruments can be used to assess the impact of skin‐related problems in SC. The TFs encourage further studies to validate HRQoL instruments for use in different stages of SC, in order to allow more detailed practical recommendations on HRQoL assessment in SC.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Wiley
ISSN:	0926-9959
Date of First Compliant Deposit:	23 April 2019
Date of Acceptance:	18 January 2019
Last Modified:	06 Nov 2023 23:44
URI:	https://orca.cardiff.ac.uk/id/eprint/121892

Actions (repository staff only)

Edit Item